This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound WATCH-LIST MEDIUM

Low-dose naltrexone

Extended Research
Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict WATCH-LIST MEDIUM

Genuine clinical signal in fibromyalgia (Younger 2013, 2014), Crohn's disease (Smith 2007, 2011), multiple sclerosis (small open-label studies). Mechanism plausible via TLR4 antagonism + endogenous opioid rebound. Cheap, low-risk, well-tolerated (rare vivid dreams + transient insomnia at start are the main complaints). For Dylan at 20 with no autoimmune/chronic pain indication, no current case. Flips to OPTIONAL-ADD if autoimmune flare or chronic pain context ever emerges — it's an unusually low-cost / low-risk first try.

Research pass: stub-manual
Verdict change log
  • 2026-06-05 — Initial verdict WATCH-LIST. (stub)

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…